In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

If you're in a relationship that faces struggles with weight and are considering GLP-1 medications like Ozempic, consider ...

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Squawk on the Street' to discuss Amgen's mid-stage trial ...

Piper Sandler's Christopher Raymond joins 'Fast Money' to talk Amgen's stock sinking on GLP-1 results. Kamala Harris ...

The Biden administration announcing Medicare and Medicaid coverage for medications such as Wegovy and Zepbound.

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

GLP-1s have been heralded for their ability to suppress appetite but did you know that GLP-1 is a natural hormone you can stimulate without injections.

(HealthDay News) — The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...